...
首页> 外文期刊>Journal of Medicinal Chemistry >Specific Inhibition of Bacterial beta-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity
【24h】

Specific Inhibition of Bacterial beta-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity

机译:通过pH依赖性方式对吡唑[4,3-c]喹啉衍生物对细菌β-葡糖醛酸酶的特异性抑制抑制化疗诱导的肠毒性

获取原文
获取原文并翻译 | 示例

摘要

The direct inhibition of bacterial,beta-glucuronidase (beta G) activity is expected to reduce the reactivation of glucuronide-conjugated drugs in the intestine, thereby reducing drug toxicity. In this study, we report on the effects of pyrazolo [4,3-c] quinolines acting as a new class of bacterial beta G-specific inhibitors in a pH-dependent manner. Refinement of this chemotype for establishing structure-activity relationship resulted in the identification of potential leads. Notably, the oral administration of 3-amino-4-(4-fluorophenylamino)-1H-pyrazolo[4,3-c]quinoline (42) combined with chemotherapeutic CPT-11 treatment prevented CPT-11-induced serious diarrhea while maintaining the antitumor efficacy in tumor-bearing mice. Importantly, the inhibitory effects of 42 to E. coli beta G was reduced as the pH decreased due to the various surface charges of the active pocket of the enzyme, which may make their combination more favorable at neutral pH. These results demonstrate novel insights into the potent bacterial beta G-specific inhibitor that would allow this inhibitor to be used for the purpose of reducing drug toxicity.
机译:预期细菌,β-葡糖醛酸糖苷酶(βG)活性的直接抑制可降低肠内葡萄糖酰胺缀合药物的再活化,从而降低药物毒性。在本研究中,我们报告了吡唑[4,3-C]喹啉作为新类细菌βG特异性抑制剂的影响,以pH依赖性方式。这种趋化型以建立结构 - 活性关系的细化导致潜在引线的识别。值得注意的是,3-氨基-4-(4-氟苯氨基)-1H-吡唑啉[4,3-氯唑啉[4,3-C]喹啉(42)联合化学治疗CPT-11治疗的口服给药可防止CPT-11诱导的严重腹泻,同时保持抗肿瘤小鼠的抗肿瘤疗效。重要的是,由于酶的活性袋的各种表面电荷导致的pH值降低,将42至大肠杆菌βG的抑制作用减少,这可以使其组合在中性pH下更有利。这些结果表明了进入有效的细菌βG特异性抑制剂的新颖见解,该抑制剂将允许该抑制剂用于减少药物毒性的目的。

著录项

  • 来源
    《Journal of Medicinal Chemistry 》 |2017年第22期| 共17页
  • 作者单位

    Natl Sun Yat Sen Univ Inst Biomed Sci Kaohsiung 804 Taiwan;

    Kaohsiung Med Univ Sch Pharm Kaohsiung 807 Taiwan;

    Natl Univ Kaohsiung Dept Life Sci Kaohsiung 811 Taiwan;

    Kaohsiung Med Univ Res Ctr Nat Prod &

    Drug Dev Kaohsiung 807 Taiwan;

    Kaohsiung Med Univ Ctr Biomarkers &

    Biotech Drugs Kaohsiung 807 Taiwan;

    Chia Nan Univ Pharm &

    Sci Dept Pharm Tainan 717 Taiwan;

    Natl Univ Kaohsiung Dept Life Sci Kaohsiung 811 Taiwan;

    Kaohsiung Med Univ Coll Med Grad Inst Clin Med Kaohsiung 807 Taiwan;

    Kaohsiung Med Univ Coll Med Grad Inst Med Kaohsiung 807 Taiwan;

    Kaohsiung Med Univ Ctr Infect Dis &

    Canc Res Kaohsiung 807 Taiwan;

    Natl Sun Yat Sen Univ Inst Biomed Sci Kaohsiung 804 Taiwan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号